Clinical Trial Update: Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating recombinant human chorionic gonadotropin (hCG) to prevent breast cancer in BRCA1 and BRCA2 mutation carriers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• recombinant hCG (human chorionic gonadotropin)

Snippet

Sponsor: University Hospital, Ghent | Conditions: hCG, BRCA1 Mutation | Phase 4 | Status: COMPLETED